Long COVID incidence declined over course of pandemic
Jul 23, 2024
The authors say, however, that the risk remained substantial, even among vaccinated persons during the omicron era.
Pandemic-linked decline in cancer screening persisted Into 2022
Feb 06, 2023
Low-dose computed tomographic scan rates and mammography rates were lower than expected during March 2021 to February 2022.
New COVID-19 cases doubled in U.S. in past three weeks
Jul 14, 2021
As cases climb, health authorities in places such as Los Angeles County and St. Louis are begging even the fully vaccinated to don their masks in public.
Adults with IBD show antibody response to mRNA COVID-19 vaccine
Nov 09, 2021
After mRNA COVID-19 vaccination, 99% of patients with inflammatory bowel disease had detectable antibodies regardless of immunocompromising therapies.
Moderna COVID-19 vaccine tied to lower adverse event risk in older adults
Aug 11, 2023
The mRNA-1273 vaccine also was tied to greater protection against COVID-19 in older adults.
Healthy, plant-based diet tied to lower COVID-19 risk
Sep 13, 2021
The association seems to be particularly pronounced among individuals living in areas with higher socioeconomic deprivation.
Circulation of respiratory viruses low during COVID-19 pandemic
Jul 23, 2021
Influenza activity decreased in March 2020 and remained low through May 2021. A decrease was seen in other viruses, with no increase until spring 2021.
mRNA COVID-19 vaccines immunogenic in immunosuppressed patients
Sep 08, 2021
mRNA-based severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines appear to be immunogenic in patients receiving immunosuppressive medications for the management of chronic inflammatory...
Observed rates of cancer diagnoses lower than expected in pandemic
Feb 26, 2024
The rate of all-sites cancer incidence was 28.6% lower than expected during the height of the COVID-19 pandemic response.
SGLT-2i use before COVID-19 may reduce adverse outcomes in diabetes patients
Dec 07, 2022
SGLT-2is are associated with the lowest probability for adverse outcomes followed by glucagon-like peptide-1 receptor agonists and metformin.